Known as the pharmacy of the world, India supplies nearly 20% of global generic volume and more than 60% of global vaccines. The country also boasts the highest number of FDA-compliant plants outside the US. Over the past five years, its pharmaceutical exports have been steadily increasing—from around $20-21 billion in the pre-pandemic period to $30.47 billion in FY25, marking a growth of over 9% year-on-year, according to official data.
More than 60% of its pharma shipments are directed to highly regulated markets, with the US accounting for roughly one-third of exports, followed by Europe and other regulated and emerging markets. Experts attribute the export growth to sustained demand for generics, vaccines, and specialty products, despite pricing pressures in some key segments.
The future also looks promising for India’s pharmaceutical market—the third largest by volume and 11th largest by value (currently $60 billion) globally—with industry estimates indicating a medium-term growth trajectory of 8-10% annually, contingent upon faster regulatory approvals and diversification into complex generics and biosimilars.
Undoubtedly, the potential is immense. However, three key things that are currently bothering the Indian pharma industry are rising compliance costs, tightening global scrutiny, and evolving trade dynamics, all of which are accelerating structural changes, especially for micro, small, and medium enterprises (MSMEs) in this sector. The shifts are also driving the sector toward higher-quality benchmarks and sector-wide consolidation.
The timing of these shifts, though, is not incidental. Industry stakeholders, including the industry body Pharmaceutical Export Promotion Council of India (Pharmexcil) and individual players such as HAB Pharma’s Director Saurabh Agarwal, maintain that the increasing global regulatory scrutiny and a volatile geopolitical environment—ranging from the West Asia conflicts to broader supply chain realignments—are reshaping export priorities for a vital sector that contributes about $30 billion annually to the country’s foreign exchange earnings.
Against this backdrop, three themes have moved sharply into focus: compliance intensity, trade-linked regulatory barriers, and ESG-linked expectations. A senior official at Pharmexcil says that global buyers are increasingly evaluating supplier reliability through the lens of compliance and continuity, not just cost. As markets turn more risk-sensitive, regulatory trust is emerging as a hedge against geopolitical uncertainty, making these shifts immediately relevant for exporters, he says.
Compliance becomes capital-heavy
At the centre of this change is a steady escalation in compliance requirements. Amid changing global trade dynamics and supply chain disruptions across geographies, pharma exporters say they have seen a marked increase in regulatory costs in the past three to five years, driven by stricter global standards, enhanced documentation protocols, and a growing emphasis on traceability.
Companies are now expected to invest in digitised quality management systems, validated software, audit trails, and end-to-end data integrity frameworks. “Regulatory compliance costs for exporters have escalated significantly over the last few years due to stricter global standards and increased scrutiny from importing regulators. Companies have had to invest heavily in improving compliance systems, traceability, and quality assurance. These increases reflect the growing need to meet higher expectations around Good Manufacturing Practices (GMP) and documentation,” says Namit Joshi, Chairman of Pharmexcil.
According to pharma companies, this increase is “not incremental” but rather “significant”; industry estimates suggest regulatory-related expenditure has risen by 15-25% over the past three to five years, depending on export exposure and product complexity. For exporters targeting regulated markets, this includes investments in data integrity systems, electronic batch records, and plant upgrades aligned with revised GMP norms, such as Schedule M.
EY India says while capital expenditure requirements may vary widely, they can cost around Rs 15-50 crore for mid-sized facilities and more than Rs 100 crore for larger export-oriented units undergoing full compliance modernisation.
Most in the industry believe that compliance is no longer a recurring cost but a structural investment cycle. A recent sectoral note by CRISIL Ratings highlighted that compliance capex is increasingly critical to market access, with balance sheet strength emerging as a key determinant of export competitiveness.
“Compliance expectations today are moving faster than margins, especially in price-sensitive segments,” says Agarwal. The revised Schedule M, India’s updated GMP framework, mandates stricter quality and compliance standards for drug manufacturing, along with stronger data integrity requirements and digitised systems, which are “no longer optional,” he adds. This is where the first major fault line emerges: MSMEs.
Regulatory overheads deepen
The rise in compliance costs is also unfolding alongside broader inflationary pressures across the pharma manufacturing value chain, further tightening margins, say industry players. “The pharmaceutical industry is facing inflationary pressures due to a 25% increase in packaging material costs, particularly for duplex and kraft boards,” says Agarwal of HAB Pharma. “Additionally, labour availability is affected by LPG shortages, as disruptions in supply are causing migrant workers to return to their native regions. These challenges are exacerbated by changing trade dynamics, impacting both production costs and labour continuity in pharmaceutical manufacturing,” he adds.
Taken together with regulatory requirements, industry stakeholders indicate that overall cost pressures have spiked significantly in recent years. While compliance-related expenditure alone is estimated to have risen by roughly 15-25% over the past three to five years, the combined impact of input cost inflation and operational disruptions is stretching balance sheets, particularly for SME exporters. A sectoral assessment by CRISIL Ratings notes that such compliance-led capex is becoming structural rather than cyclical, effectively raising the entry barrier for exporters targeting regulated markets.
Industry stakeholders broadly agree that smaller exporters are disproportionately impacted. Limited financial buffers and operational bandwidth make it harder for them to adapt quickly to regulatory frameworks. The shift towards digital platforms, stricter audit requirements, and compressed timelines has further compounded the challenge.
“MSME pharma exporters are disproportionately impacted by stricter global norms,” says Joshi, adding that limited resources and operational agility make it difficult to keep pace with evolving regulations. He further underlines that the absence of transition periods, along with the shift to digital compliance platforms, has added to the burden on smaller players.
Notably, MSMEs form a substantial base of India’s pharma manufacturing ecosystem, accounting for an estimated 30-40% of production, but their share in exports is relatively lower compared to large firms, notes the India Brand Equity Foundation.
Industry bodies, including Pharmexcil, highlight that while MSMEs are deeply embedded in formulations, APIs and emerging market supplies, exports to highly regulated markets remain concentrated among larger players with stronger compliance capabilities. Pharmexcil’s Chairman further maintains that while MSMEs contribute nearly 45-48% of India’s total exports across sectors, underscoring their systemic importance, this share is not fully mirrored in pharmaceuticals due to regulatory entry barriers.
The implications of such uneven operational turf are already visible across the pharma ecosystem. According to industry stakeholders, a phase of consolidation seems more likely as companies struggle to absorb rising compliance costs. Firms with strong balance sheets and established compliance infrastructure are better positioned to scale, while smaller units may be forced to merge, pivot or exit. “Consolidation is very likely as smaller players operating on thin margins will find it difficult to absorb rising compliance investments. As Indian standards move closer to global GMP expectations, some units will struggle, merge or exit,” flags Agarwal.
While this consolidation may be painful in the near term, industry officials say that it could ultimately strengthen India’s pharma manufacturing base. They emphasise that a more compliant and transparent ecosystem would enhance global trust, which is increasingly central to India’s positioning in global markets.
For decades, India’s identity as the “pharmacy of the world” has been anchored in its ability to supply affordable generics at scale. That advantage, industry observers argue, is no longer sufficient as global buyers, particularly in regulated markets such as the US and Europe, are placing increasing weight on regulatory trust, consistency and quality assurance. A recent assessment by India Ratings and Research noted that the next phase of the sector’s export growth will be increasingly driven by value addition rather than volume expansion.
According to Mohan Jain, Director at Naprod Life Sciences, the country’s positioning as the pharmacy of the world is increasingly shifting from price competitiveness to regulatory trust. “We note global markets placing greater emphasis on quality assurance and compliance with stringent GMP standards. The success of the firms in this sector will depend on maintaining high standards of quality, safety and transparency,” he underscores.
Industry observers further emphasise that the sector’s price competitiveness is being complemented, and in some cases overshadowed, by expectations around GMP, data integrity and transparency. This transition reflects a broader trend in global healthcare procurement, where reliability and compliance are emerging as non-negotiable criteria.
Trade policy meets regulatory friction
The geopolitical dimension adds another layer of complexity to this discussion. As competition intensifies in the generics space, particularly with more drugs going off patent, there is a growing possibility that regulatory standards could be used as strategic trade tools. Industry players acknowledge this risk but suggest that the response should not be defensive. Instead, the emphasis, they assert, should be on capability building.
“There is always a possibility that regulatory standards can be used strategically, especially in the generics space,” Agarwal says. “However, the answer is not resistance but capability. When quality is unquestionable and systems are robust, technical barriers become less effective as a strategic tool.”
Trade policies are also evolving in this context. For example, free trade agreements (FTAs), traditionally focused on tariffs, are increasingly being viewed through the lens of regulatory harmonisation. For pharma exporters, faster approvals, mutual recognition of inspections and alignment of GMP standards are far more consequential than duty reductions. According to Agarwal, regulatory harmonisation should be central to any trade negotiations the country undertakes. “For pharmaceuticals, regulatory alignment is far more critical than tariffs,” Agarwal says, stressing that what truly helps exporters is faster approvals, mutual recognition of inspections, and reduced duplication in documentation.
Execution gaps, ESG pressures rise
Experts say while India’s regulatory framework has moved closer to global standards, perception challenges persist. Issues such as inconsistent documentation requirements across states and delays in certification processes create uncertainty for exporters and their global partners. “India’s domestic regulatory framework is increasingly aligned with global standards, but perception gaps persist. Challenges such as inconsistent documentation and delays in approvals affect predictability,” says Pharmexcil’s Joshi, adding that these concerns need to be addressed to boost global confidence in Indian manufacturers.
Notably, efforts are underway to address these concerns through digitisation, policy dialogues and institutional coordination, though execution remains uneven, say industry observers. “The government has been proactive in supporting exporters, though the effectiveness varies. Policy dialogues and initiatives are helping address bottlenecks, but delays and inconsistencies still need to be resolved,” Joshi adds. He opines that better coordination between central and state authorities will be key.
Even as the industry grapples with current regulatory pressures, a new frontier is taking shape: ESG-linked norms.
Global markets are increasingly incorporating environmental, social and governance (ESG) criteria into their procurement and compliance frameworks. For Indian pharma companies, this introduces an additional layer of complexity, particularly for mid-sized and smaller firms that are still building foundational systems.
“The industry is still in the early stages of preparing for stricter ESG-linked export norms,” Napod’s Jain says. He highlights that while larger companies are integrating sustainability practices, many MSMEs will need time to build robust frameworks around this concept. “As global markets place greater emphasis on ESG, Indian pharma must accelerate its adoption to stay competitive,” he adds.
